Oncologist perspectives on chemotherapy‐induced nausea and vomiting (CINV) management and outcomes: A quantitative market research‐based survey

Chemotherapy‐induced nausea and vomiting (CINV) is a distressing side effect that can negatively impact patients' quality of life and could discourage completion of chemotherapy, thereby affecting overall treatment outcomes. Although adherence to antiemetic guidelines can reduce CINV incidence in patients receiving highly or moderately emetogenic chemotherapy, CINV control remains inadequate.

• Publication year

  2018

• Venue

  Cancer Reports

• Publication date

  2018-10-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cnr2.1127PMID 32729252PMCID 7941545
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey

  2019cited by this paper
• Oncologist perspectives on chemotherapy‐induced nausea and vomiting (CINV) management and outcomes: A quantitative market research‐based survey

  2018cited by this paper
• The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting

  2017cited by this paper
• Identifying predictive factors of chemotherapy-induced nausea and vomiting (CINV): a novel approach.

  2017cited by this paper
• Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update.

  2017cited by this paper
• Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses

  2017cited by this paper
• 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.

  2016cited by this paper
• Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron

  2016cited by this paper
• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

  2016cited by this paper
• Anticipatory Nausea, Risk Factors, and Its Impact on Chemotherapy-Induced Nausea and Vomiting: Results From the Pan European Emesis Registry Study.

  2016influential reference
• Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional multinational survey

  2015influential reference
• Treatment of Hypertensive Patients with a Fixed-Dose Combination of Bisoprolol and Amlodipine: Results of a Cohort study with More Than 10,000 Patients

  2015cited by this paper
• A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

  2014cited by this paper
• Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.

  2014influential reference
• Systematic review and meta‐analysis: Patient and programme impact of fixed‐dose combination antiretroviral therapy

  2014cited by this paper
• International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice.

  2014cited by this paper
• Factors affecting patient's perception of anticancer treatments side-effects: an observational study

  2014cited by this paper
• Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study.

  2014cited by this paper
• NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines

  2014cited by this paper
• Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting

  2013cited by this paper
• The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).

  2012cited by this paper
• National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

  2012cited by this paper
• The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life

  2012cited by this paper
• The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).

  2012cited by this paper
• Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives.

  2012cited by this paper
• Assessment of the Relationship Between Adherence with Antiemetic Drug Therapy and Control of Nausea and Vomiting in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy

  2012cited by this paper
• Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists

  2011cited by this paper
• Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC)

  2011cited by this paper
• Patient adherence and persistence with oral anticancer treatment

  2009cited by this paper
• Impact of Fixed-Dose Combination Drugs on Adherence to Prescription Medications

  2008cited by this paper
• Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool.

  2007cited by this paper
• Randomised controlled trials in general practice

  1995cited by this paper
• Cancer Management and Research Dovepress the Impact of 5-hydroxytryptamine-receptor Antagonists on Chemotherapy Treatment Adherence, Treatment Delay, and Nausea and Vomiting

  year unknowncited by this paper

• Bioequivalence of netupitant and palonosetron (NEPA) oral suspension and hard capsules in healthy individuals: results from an open-label, randomized, two-treatment, four-period, two-sequence replicative design trial

  2026cites this paper
• Development and validation of the “FeiChangHeHu” WeChat mini-program for real-time management of chemotherapy-induced nausea and vomiting in lung cancer patients

  2026cites this paper
• Expert Consensus Guidance on the Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective

  2025cites this paper
• Chemotherapy-induced nausea and vomiting symptom experience in patients with non-small-cell lung cancer: A qualitative study

  2025cites this paper
• A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial

  2025cites this paper
• Correction: Hepatic IRE1α-XBP1 signaling promotes GDF15-mediated anorexia and body weight loss in chemotherapy

  2025cites this paper
• Design of a Randomized Sham-Controlled Trial: Strengthening Positive Treatment Expectations Using a Communication Model for Maximized Antiemetic Effects of Acupuncture and Antiemetics During Emetogenic Neo-/Adjuvant Chemotherapy

  2025cites this paper
• Neurokinin-1 receptor antagonists in the current management of chemotherapy-induced nausea and vomiting

  2025cites this paper
• Review of the Use of Medicinal Cannabis Products in Palliative Care

  2024cites this paper
• Challenges in chemotherapy induced nausea and vomiting (CINV) management: A systematic review

  2024influential citation
• Antiemetic prophylaxis regimens in haematologic malignancies patients undergoing a hematopoietic stem cell transplantation. Which is the best standard of care? A systematic review

  2024cites this paper
• Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: the road to success.

  2024cites this paper
• Hepatic IRE1α-XBP1 signaling promotes GDF15-mediated anorexia and body weight loss in chemotherapy

  2024cites this paper
• Adherence to antiemetic guidelines in solid cancer patients receiving highly emetogenic chemotherapy in Korea

  2024cites this paper
• Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal

  2023cites this paper
• Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation

  2023cites this paper
• Akynzeo® (netupitant/palonosetron) as a basis of modern prophylaxis of chemotherapy-induced nausea and vomiting

  2023cites this paper
• Possibilities of prevention of nausea during cytostatic therapy: literature review and clinical cases

  2023cites this paper
• [Translated article] Have changes concerning carboplatin and anthracyclines been incorporated?

  2023cites this paper
• Antiemetic guidelines: Have we incorporated the changes concerning carboplatin and anthracyclines?

  2023cites this paper
• Assessment and management of nausea and vomiting in cancer survivors

  2023cites this paper
• Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy.

  2023cites this paper
• Emetogenicity of Chemotherapy Regimens and Recommended Prophylaxis: A Review of MASCC/ESMO Guidelines

  2022cites this paper
• Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting: Results of the nausea/emesis registry in oncology (NERO).

  2022cites this paper
• Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice

  2022cites this paper
• Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data.

  2021cites this paper
• A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers

  2021cites this paper
• Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy

  2021cites this paper
• Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience

  2021cites this paper
• Acupuncture treatment for nausea and vomiting after chemotherapy

  2021cites this paper
• Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy

  2021cites this paper
• Acupoint selection rules in treatment of chemotherapy-induced nausea and vomiting with acupuncture and moxibustion

  2021cites this paper
• A cross-sectional study on the guideline adherence to antiemetic regimens for chemotherapy-induced nausea and vomiting: A single center retrospective study of 1000 patients.

  2021cites this paper
• Prevention of chemotherapy-induced nausea and vomiting in the real-world setting in Spain

  2021influential citation
• Practical insight into the current management of chemotherapy induce nausea and vomiting: An indian survey

  2021cites this paper
• Evaluation of patient quality care in Spain in prevention of nausea and vomiting induced by chemotherapy.

  2021cites this paper
• GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates.

  2020cites this paper
• Phase 3 study of palonosetron intravenous (IV) infusion versus IV bolus for chemotherapy-induced nausea and vomiting prophylaxis following highly emetogenic chemotherapy.

  2020cites this paper
• Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Recommendations, and New Trends.

  2020cites this paper
• Real-world evidence of NEPA, netupitant-palonosetron, in chemotherapy-induced nausea and vomiting prevention: effects on quality of life.

  2020cites this paper
• Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.

  2019cites this paper
• Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies

  2019cites this paper
• Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey

  2019cites this paper
• Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: Prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy.

  2019cites this paper
• Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults

  2019cites this paper
• Oncologist perspectives on chemotherapy‐induced nausea and vomiting (CINV) management and outcomes: A quantitative market research‐based survey

  2018cites this paper
• Nurses' knowledge, attitude and practice of chemotherapy-induced nausea and vomiting in Shanghai China: a cross-sectional study

  year unknowncites this paper